Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rhythm Biosciences Ltd, an Australian firm specializing in pioneering cancer diagnostic technologies, has successfully closed a shortfall offer related to their recent rights issue, raising a total of $2,745,416. The company expressed gratitude to both new and existing shareholders for their participation. This capital raise is aimed at advancing the development and distribution of their ColoSTAT® Test-Kit for early detection of colorectal cancer, which is based on significant research and has international patent protection.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.